Analysts Set Cognition Therapeutics, Inc. (NASDAQ:CGTX) PT at $3.33

Cognition Therapeutics, Inc. (NASDAQ:CGTX) has been given an average rating of “Moderate Buy” by the four brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $3.3333.

Several equities analysts have weighed in on the company. Chardan Capital restated a “buy” rating and set a $4.00 price objective on shares of Cognition Therapeutics in a research note on Friday, March 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Cognition Therapeutics in a research note on Friday, March 27th.

Hedge Funds Weigh In On Cognition Therapeutics

Large investors have recently bought and sold shares of the stock. Jones Financial Companies Lllp bought a new position in Cognition Therapeutics during the 3rd quarter valued at $25,000. Essex Financial Services Inc. bought a new position in Cognition Therapeutics during the 4th quarter valued at $27,000. Gamco Investors INC. ET AL bought a new position in Cognition Therapeutics during the 3rd quarter valued at $27,000. Private Management Group Inc. bought a new position in Cognition Therapeutics during the 3rd quarter valued at $32,000. Finally, Marshall Wace LLP bought a new position in Cognition Therapeutics during the 4th quarter valued at $37,000. 43.35% of the stock is currently owned by institutional investors.

Cognition Therapeutics Price Performance

Shares of CGTX opened at $1.21 on Wednesday. Cognition Therapeutics has a 12-month low of $0.25 and a 12-month high of $3.83. The business’s fifty day moving average is $1.16 and its 200 day moving average is $1.24. The stock has a market cap of $108.30 million, a P/E ratio of -5.04 and a beta of 1.75.

Cognition Therapeutics (NASDAQ:CGTX) last issued its earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. On average, analysts expect that Cognition Therapeutics will post -0.32 EPS for the current year.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.